Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.

Patel NS, Oury A, Daniels GA, Bazhenova L, Patel SP.

Oncologist. 2018 May 16. pii: theoncologist.2017-0375. doi: 10.1634/theoncologist.2017-0375. [Epub ahead of print]

PMID:
29769383
2.

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

Camidge DR, Kim DW, Tiseo M, Langer CJ, Ahn MJ, Shaw AT, Huber RM, Hochmair MJ, Lee DH, Bazhenova LA, Gold KA, Ou SI, West HL, Reichmann W, Haney J, Clackson T, Kerstein D, Gettinger SN.

J Clin Oncol. 2018 May 16:JCO2017775841. doi: 10.1200/JCO.2017.77.5841. [Epub ahead of print]

PMID:
29768119
3.

Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).

Urbanic JJ, Wang X, Bogart JA, Stinchcombe TE, Hodgson L, Schild SE, Bazhenova L, Hahn O, Salgia R, Vokes EE.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):177-185. doi: 10.1016/j.ijrobp.2018.01.046. Epub 2018 Jan 31.

PMID:
29487024
4.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials.

Goss G, Tsai CM, Shepherd FA, Ahn MJ, Bazhenova L, Crinò L, de Marinis F, Felip E, Morabito A, Hodge R, Cantarini M, Johnson M, Mitsudomi T, Jänne PA, Yang JC.

Ann Oncol. 2018 Mar 1;29(3):687-693. doi: 10.1093/annonc/mdx820.

PMID:
29293889
5.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR.

Lancet Oncol. 2018 Jan;19(1):101-114. doi: 10.1016/S1470-2045(17)30694-0. Epub 2017 Nov 20.

6.

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors.

Subbiah V, Grilley-Olson JE, Combest AJ, Sharma N, Tran RH, Bobe I, Osada A, Takahashi K, Balkissoon J, Camp A, Masada A, Reitsma DJ, Bazhenova LA.

Clin Cancer Res. 2018 Jan 1;24(1):43-51. doi: 10.1158/1078-0432.CCR-17-1114. Epub 2017 Oct 13.

PMID:
29030354
7.

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R.

Clin Cancer Res. 2017 Oct 1;23(19):5729-5736. doi: 10.1158/1078-0432.CCR-17-1439.

PMID:
28972084
8.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

PMID:
28835386
9.

Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing.

Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R.

Cancer Res. 2017 Oct 1;77(19):5419-5427. doi: 10.1158/0008-5472.CAN-17-0885. Epub 2017 Aug 14.

PMID:
28807936
10.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Engstrom LD, Aranda R, Lee M, Tovar EA, Essenburg CJ, Madaj Z, Chiang H, Briere D, Hallin J, Lopez-Casas PP, Baños N, Menendez C, Hidalgo M, Tassell V, Chao R, Chudova DI, Lanman RB, Olson P, Bazhenova L, Patel SP, Graveel C, Nishino M, Shapiro GI, Peled N, Awad MM, Jänne PA, Christensen JG.

Clin Cancer Res. 2017 Nov 1;23(21):6661-6672. doi: 10.1158/1078-0432.CCR-17-1192. Epub 2017 Aug 1.

PMID:
28765324
11.

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma.

Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R.

Clin Cancer Res. 2017 Sep 1;23(17):5101-5111. doi: 10.1158/1078-0432.CCR-16-2497. Epub 2017 May 24.

PMID:
28539465
12.

Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.

Boffa DJ, Graf RP, Salazar MC, Hoag J, Lu D, Krupa R, Louw J, Dugan L, Wang Y, Landers M, Suraneni M, Greene SB, Magaña M, Makani S, Bazhenova L, Dittamore RV, Nieva J.

Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1139-1145. doi: 10.1158/1055-9965.EPI-17-0120. Epub 2017 Apr 26.

13.

Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR.

Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8.

PMID:
27836716
14.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, Han JY, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T.

Lancet Oncol. 2016 Dec;17(12):1643-1652. doi: 10.1016/S1470-2045(16)30508-3. Epub 2016 Oct 14.

PMID:
27751847
15.

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.

Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM.

Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8.

16.

Ovarian stimulation in young adult cancer survivors on targeted cancer therapies.

Su HI, Connell MW, Bazhenova LA.

Fertil Steril. 2016 Nov;106(6):1475-1478. doi: 10.1016/j.fertnstert.2016.08.011. Epub 2016 Aug 24. Review.

17.

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2016 Jul;14(7):825-36.

PMID:
27407123
18.

190TiP: ELUXA 1: Phase II study of BI 1482694 (HM61713) in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI).

Park K, Han JY, Kim DW, Bazhenova LA, Ou SH, Pang YK, Hin HS, Juan O, Son J, Jänne P.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S139. doi: 10.1016/S1556-0864(16)30299-4. Epub 2016 Apr 15. No abstract available.

19.

1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial.

Rosell R, Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Shaw AT, Narasimhan NI, Dorer DJ, Kerstein D, Camidge DR.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S114. doi: 10.1016/S1556-0864(16)30245-3. Epub 2016 Apr 15. No abstract available.

20.

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2016 Mar;14(3):255-64.

PMID:
26957612
21.

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.

22.

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology.

Patel SP, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R.

Oncotarget. 2015 Oct 20;6(32):32602-9. doi: 10.18632/oncotarget.5289.

23.

A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

Giaccone G, Bazhenova LA, Nemunaitis J, Tan M, Juhász E, Ramlau R, van den Heuvel MM, Lal R, Kloecker GH, Eaton KD, Chu Q, Dunlop DJ, Jain M, Garon EB, Davis CS, Carrier E, Moses SC, Shawler DL, Fakhrai H.

Eur J Cancer. 2015 Nov;51(16):2321-9. doi: 10.1016/j.ejca.2015.07.035. Epub 2015 Aug 14.

PMID:
26283035
24.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

Lung Cancer. 2015 Sep;89(3):357-9. doi: 10.1016/j.lungcan.2015.06.021. Epub 2015 Jun 29.

PMID:
26187428
25.

Non-Small Cell Lung Cancer, Version 6.2015.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 May;13(5):515-24.

PMID:
25964637
26.

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer.

Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R.

Oncotarget. 2015 Mar 20;6(8):6029-39.

27.

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.

Kato S, Schwaederle M, Daniels GA, Piccioni D, Kesari S, Bazhenova L, Shimabukuro K, Parker BA, Fanta P, Kurzrock R.

Cell Cycle. 2015;14(8):1252-9. doi: 10.1080/15384101.2015.1014149.

28.

Entropy, complexity, and Markov diagrams for random walk cancer models.

Newton PK, Mason J, Hurt B, Bethel K, Bazhenova L, Nieva J, Kuhn P.

Sci Rep. 2014 Dec 19;4:7558. doi: 10.1038/srep07558.

29.

Non-small cell lung cancer, version 1.2015.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M.

J Natl Compr Canc Netw. 2014 Dec;12(12):1738-61.

PMID:
25505215
30.

The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation.

Phillips KG, Lee AM, Tormoen GW, Rigg RA, Kolatkar A, Luttgen M, Bethel K, Bazhenova L, Kuhn P, Newton P, McCarty OJ.

Am J Physiol Cell Physiol. 2015 Feb 1;308(3):C229-36. doi: 10.1152/ajpcell.00315.2014. Epub 2014 Nov 19.

31.

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.

Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.

Clin Cancer Res. 2014 Dec 1;20(23):5927-36. doi: 10.1158/1078-0432.CCR-14-0804. Epub 2014 Sep 17.

32.

Circulating tumor microemboli diagnostics for patients with non-small-cell lung cancer.

Carlsson A, Nair VS, Luttgen MS, Keu KV, Horng G, Vasanawala M, Kolatkar A, Jamali M, Iagaru AH, Kuschner W, Loo BW Jr, Shrager JB, Bethel K, Hoh CK, Bazhenova L, Nieva J, Kuhn P, Gambhir SS.

J Thorac Oncol. 2014 Aug;9(8):1111-9. doi: 10.1097/JTO.0000000000000235.

33.

Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study.

Scott BJ, van Vugt VA, Rush T, Brown T, Chen CC, Carter BS, Schwab R, Fanta P, Helsten T, Bazhenova L, Parker B, Pingle S, Saria MG, Brown BD, Piccioni DE, Kesari S.

J Neurooncol. 2014 Sep;119(2):361-8. doi: 10.1007/s11060-014-1486-2. Epub 2014 Jun 19.

PMID:
24942463
34.

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.

Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R.

Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5.

35.

Adrenal metastases in lung cancer: clinical implications of a mathematical model.

Bazhenova L, Newton P, Mason J, Bethel K, Nieva J, Kuhn P.

J Thorac Oncol. 2014 Apr;9(4):442-6. doi: 10.1097/JTO.0000000000000133. Review.

36.

Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.

Haidar YM, Rahn DA 3rd, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP.

Ther Adv Respir Dis. 2014 Feb;8(1):3-12. doi: 10.1177/1753465813512545. Epub 2013 Dec 10.

PMID:
24334338
37.

Stereotactic body radiation therapy in octogenarians with stage I lung cancer.

Sandhu AP, Lau SK, Rahn D, Nath SK, Kim D, Song WY, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ.

Clin Lung Cancer. 2014 Mar;15(2):131-5. doi: 10.1016/j.cllc.2013.08.007. Epub 2013 Oct 21.

PMID:
24157245
38.

An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.

Nair VS, Keu KV, Luttgen MS, Kolatkar A, Vasanawala M, Kuschner W, Bethel K, Iagaru AH, Hoh C, Shrager JB, Loo BW Jr, Bazhenova L, Nieva J, Gambhir SS, Kuhn P.

PLoS One. 2013 Jul 5;8(7):e67733. doi: 10.1371/journal.pone.0067733. Print 2013.

39.

Hypersensitivity reactions to carboplatin and cisplatin in non-small cell lung cancer.

Randall JM, Bharne AA, Bazhenova LA.

J Thorac Dis. 2013 Apr;5(2):E53-7. doi: 10.3978/j.issn.2072-1439.2012.06.12.

40.

Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model.

Newton PK, Mason J, Bethel K, Bazhenova L, Nieva J, Norton L, Kuhn P.

Cancer Res. 2013 May 1;73(9):2760-9. doi: 10.1158/0008-5472.CAN-12-4488. Epub 2013 Feb 27.

41.

Clinic-based depression screening in lung cancer patients using the PHQ-2 and PHQ-9 depression questionnaires: a pilot study.

Randall JM, Voth R, Burnett E, Bazhenova L, Bardwell WA.

Support Care Cancer. 2013 May;21(5):1503-7. doi: 10.1007/s00520-012-1712-4. Epub 2013 Jan 17.

PMID:
23325092
42.
43.

A stochastic Markov chain model to describe lung cancer growth and metastasis.

Newton PK, Mason J, Bethel K, Bazhenova LA, Nieva J, Kuhn P.

PLoS One. 2012;7(4):e34637. doi: 10.1371/journal.pone.0034637. Epub 2012 Apr 27.

44.

Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology.

Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, Honnatti M, Cho EH, Marrinucci D, Sandhu A, Perricone A, Thistlethwaite P, Bethel K, Nieva J, Heuvel Mv, Kuhn P.

Phys Biol. 2012 Feb;9(1):016005. doi: 10.1088/1478-3967/9/1/016005. Epub 2012 Feb 3.

45.

High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis.

Nieva J, Wendel M, Luttgen MS, Marrinucci D, Bazhenova L, Kolatkar A, Santala R, Whittenberger B, Burke J, Torrey M, Bethel K, Kuhn P.

Phys Biol. 2012 Feb;9(1):016004. doi: 10.1088/1478-3975/9/1/016004. Epub 2012 Feb 3.

46.

Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers.

Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P.

Phys Biol. 2012 Feb;9(1):016003. doi: 10.1088/1478-3975/9/1/016003. Epub 2012 Feb 3.

47.

Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors.

Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P.

Phys Biol. 2012 Feb;9(1):016001. doi: 10.1088/1478-3975/9/1/016001. Epub 2012 Feb 3.

48.

Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases.

Kim D, Fuster MM, Nath SK, Bharne A, Read W, Bazhenova L, Song WY, Mundt AJ, Sandhu AP.

J Radiosurg SBRT. 2012;2(1):63-72.

49.

Clinical outcomes following image-guided stereotactic body radiation for pulmonary oligometastases.

Kim D, Fuster MM, Nath SK, Bharne A, Read W, Bazhenova L, Song WY, Mundt AJ, Sandhu AP.

J Radiosurg SBRT. 2012;1(4):317-325.

50.

Frameless image-guided stereotactic body radiation therapy for lung tumors with 4-dimensional computed tomography or 4-dimensional positron emission tomography/ computed tomography.

Nath SK, Sandhu AP, Jensen L, Kim D, Bharne A, Nobiensky PD, Lawson JD, Fuster MM, Bazhenova L, Song WY, Mundt AJ.

Clin Lung Cancer. 2011 May;12(3):180-6. doi: 10.1016/j.cllc.2011.03.014. Epub 2011 Apr 24.

PMID:
21663861

Supplemental Content

Loading ...
Support Center